comparemela.com

Latest Breaking News On - இரண்டு சிக்மா முயற்சிகள் - Page 4 : comparemela.com

Biotech startup using AI to take guesswork out of cancer drug selection raises $70M

Xilis, Inc : Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere Technology

Xilis, Inc : Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere Technology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Durham medtech startup Xilis raises $70M; Google Ventures, Duke Angels among backers

Durham medtech startup Xilis raises $70M; Google Ventures, Duke Angels among backers
wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.

Follow the Money: AI-Powered Drug Discovery, Remote Access Labs

July 1, 2021 July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more. $550M: VC Fund for Therapeutics for Unmet Needs venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.